AI
Saturday, January 03, 2009 5:05:06 PM
5 more trading days to $0.7...
A bit optimistic perhaps but my guess is that we will get a unanimous recommendation for approval by the advisory panel on Jan 9. That does not mean that the FDA will necessarrilly approve following a positive advisory recommendation (recall Provenge's DNDN) but I think in this case the FDA will follow the recommendation because there are no big pharma politics involved with ATryn, the trial results are convincing, and the need is there...
I was previously of the opinion that the LFB financing deal put us investors at risk for an LFB takeover on the cheap ($0.31) by next summer, but I am now rethinking my stand because approval will inject $4 Million at a minimum from Ovation and then we will have at least two suitors, namely LFB and Ovation. Moreover, an FOB partnership following ATryn FDA approval with strong upfront cash becomes quite probable as it would be a strong validation of GTCB's transgenic technology. In that case, perhaps GTCB will be able afterall to repay the loan to LFB and keep its intellectual properties and stay independent! Maybe management is not as dumb as they have seemed lately...LOL...
A bit optimistic perhaps but my guess is that we will get a unanimous recommendation for approval by the advisory panel on Jan 9. That does not mean that the FDA will necessarrilly approve following a positive advisory recommendation (recall Provenge's DNDN) but I think in this case the FDA will follow the recommendation because there are no big pharma politics involved with ATryn, the trial results are convincing, and the need is there...
I was previously of the opinion that the LFB financing deal put us investors at risk for an LFB takeover on the cheap ($0.31) by next summer, but I am now rethinking my stand because approval will inject $4 Million at a minimum from Ovation and then we will have at least two suitors, namely LFB and Ovation. Moreover, an FOB partnership following ATryn FDA approval with strong upfront cash becomes quite probable as it would be a strong validation of GTCB's transgenic technology. In that case, perhaps GTCB will be able afterall to repay the loan to LFB and keep its intellectual properties and stay independent! Maybe management is not as dumb as they have seemed lately...LOL...
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
